Antitrust Enforcement In Health Care: A Risky And Evolving Landscape
In the last 18 months, seven companies and four executives in the generic pharmaceuticals manufacturing sector were charged with antitrust violations, amassing penalties of over $426m. And this month, the Department of Justice Antitrust Division brought its first ever criminal charges for a conspiracy to lower wages to workers against the former owner of a physical therapist staffing company. With enforcement efforts ramping up – and COVID-19 adding additional scrutiny – health care companies will need a comprehensive antitrust compliance program to avoid enforcement actions.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Supreme Court’s six conservative justices say Constitution doesn’t guarantee a woman’s right to abortion services nor prohibit states from regulating or banning the services. Dissenting liberal members decry decision as erasing women’s constitutional rights.